Unicorn Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.59 Cr
as on 16-11-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.10 Cr
as on 16-11-2024
- Revenue -15.49%
(FY 2023)
- Profit 132.04%
(FY 2023)
- Ebitda -391.20%
(FY 2023)
- Net Worth 6.06%
(FY 2023)
- Total Assets -20.76%
(FY 2023)
About Unicorn Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 3.59 Cr.
The company currently has active open charges totaling ₹7.10 Cr.
Vijay Dave, Haridasan Raman, Jatin Shah, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC154558
- Company No.
154558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jul 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Unicorn Pharmachem Private Limited offer?
Unicorn Pharmachem Private Limited offers a wide range of products and services, including API (Active Pharmaceutical Ingredients), Pharmaceutical Tablets, Sublingual Tablets, Pharma Ingredients & Raw Materials, Vitamin Powder API, Common Disease Medicines, Pharmaceutical Medicine, Anti Infective API, Vitamin & Multivitamin Injections, Vitamin C injection.
Who are the key members and board of directors at Unicorn Pharmachem?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Dave  | Director | 16-Feb-2008 | Current |
| Haridasan Raman | Director | 07-Jul-2005 | Current |
| Jatin Shah | Director | 07-Jul-2005 | Current |
| Bhavesh Shah | Director | 07-Jul-2005 | Current |
| Kamal Patcha | Director | 07-Jul-2005 | Current |
| Raj Chakravarty | Director | 16-Feb-2008 | Current |
Financial Performance of Unicorn Pharmachem.
Unicorn Pharmachem Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.49% decrease. The company also saw a substantial improvement in profitability, with a 132.04% increase in profit. The company's net worth moved up by a moderate rise of 6.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unicorn Pharmachem?
In 2023, Unicorn Pharmachem had a promoter holding of 87.74% and a public holding of 12.25%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Draco Lifesciences Private LimitedActive 13 years 4 monthsVijay Dave, Bhavesh Shah and 1 more are mutual person
- Harikamal Exim Logistics Private LimitedActive 22 years 3 months
Haridasan Raman and Kamal Patcha are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Saraswat Co-Operative Bank Ltd Creation Date: 27 May 2011 | ₹1.10 Cr | Open |
Others Creation Date: 12 Mar 2010 | ₹6.00 Cr | Open |
How Many Employees Work at Unicorn Pharmachem?
Unlock and access historical data on people associated with Unicorn Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unicorn Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unicorn Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
